21 research outputs found
Functional Modulation of Vascular Adhesion Protein-1 by a Novel Splice Variant
<div><p>Vascular Adhesion Protein-1 (VAP-1) is an endothelial adhesion molecule belonging to the primary amine oxidases. Upon inflammation it takes part in the leukocyte extravasation cascade facilitating transmigration of leukocytes into the inflamed tissue. Screening of a human lung cDNA library revealed the presence of an alternatively spliced shorter transcript of VAP-1, VAP-1Δ3. Here, we have studied the functional and structural characteristics of VAP-1Δ3, and show that the mRNA for this splice variant is expressed in most human tissues studied. In comparison to the parent molecule this carboxy-terminally truncated isoform lacks several of the amino acids important in the formation of the enzymatic groove of VAP-1. In addition, the conserved His684, which takes part in coordinating the active site copper, is missing from VAP-1Δ3. Assays using the prototypic amine substrates methylamine and benzylamine demonstrated that VAP-1Δ3 is indeed devoid of the semicarbazide-sensitive amine oxidase (SSAO) activity characteristic to VAP-1. When VAP-1Δ3-cDNA is transfected into cells stably expressing VAP-1, the surface expression of the full-length molecule is reduced. Furthermore, the SSAO activity of the co-transfectants is diminished in comparison to transfectants expressing only VAP-1. The observed down-regulation of both the expression and enzymatic activity of VAP-1 may result from a dominant-negative effect caused by heterodimerization between VAP-1 and VAP-1Δ3, which was detected in co-immunoprecipitation studies. This alternatively spliced transcript adds thus to the repertoire of potential regulatory mechanisms through which the cell-surface expression and enzymatic activity of VAP-1 can be modulated.</p> </div
Expression of VAP-1Δ3 in transiently transfected cell lines.
<p>Flow cytometry of HEK293 cells transfected either with the full-length VAP-1- or with VAP-1Δ3 -cDNAs in pcDNA3.1 (<b>A–B</b>). The <i>gray</i> histograms: staining with the anti-VAP-1 polyclonal antibody; the <i>black</i> histograms: staining with a negative control antibody. The expression was also examined by fluorescence microscopy of acetone-permeabilized coverslip-plated HEK293 cells transfected with the corresponding constructs (<b>C–D</b>). In <b>E–F</b>, flow cytometry of HUVECs infected with pAdCMV-constructs of VAP-1- and VAP-1Δ3. The <i>gray</i> histograms: staining with the anti-VAP-1 polyclonal antibody; the <i>black</i> histograms: staining with a negative control antibody. The expression was also examined by fluorescence microscopy of acetone-permeabilized coverslip-plated HUVECs infected with the corresponding constructs (<b>G–H</b>). Scale bar 100 µm.</p
Heterodimerisation of VAP-1 and VAP-1 Δ3.
<p>Lysates of HEK293 cells co-transfected with flag-tagged VAP-1 cDNA, myc-tagged VAP-1Δ3 cDNA or with the corresponding tagged empty vectors in different combinations were separated in SDS-PAGE (with or without prior immunoprecipitation) and blotted to nitrocellulose membranes. The functionality of the tagged constructs and the ability to detect the proteins with corresponding antibodies was first verified by using the flag-antibody (A) or the myc-antibody (B) in control gels without prior immunoprecipitations. Aliquots of the same lysates were then immunoprecipitated with the flag antibody prior to gel electrophoresis, and the immunoprecipitated product was detected using the myc-antibody (<b>C</b>). The sizes of the two VAP-1 isoforms and the molecular weight markers are indicated. <i>Ip</i> Immunoprecipitation, <i>Ig</i> Immunoglobulin.</p
Enzymatic activities of the two VAP-1 isoforms.
<p>The SSAO-activity and substrate specificities of VAP-1 and VAP-1Δ3 were defined by a fluorometric assay from lysed transfectants. (<b>A</b>) HEK293 cells transfected with VAP-1. (<b>B</b>) HEK293 cells transfected with VAP-1Δ3 (<b>C</b>) HUVECs infected with VAP-1 (<b>D</b>) HUVECs infected with VAP-1Δ3. The final concentrations of all substrates were 1 mM. <i>MA</i> methylamine; <i>BZ</i> benzylamine; <i>TYR p-</i>tyramine; <i>TRYPT</i> tryptamine; <i>PEA</i> 2-phenylethylamine; <i>HIS</i> histamine. The results are expressed as nmol/mg/h+standard deviation (SD) (n = 3). (<b>E</b>) The structure of dimeric VAP-1 (PDB code 1US1; Airenne et al., 2002), viewed from the side of the carboxy-terminus along the two-fold axis. Both monomers are drawn in rainbow colors from blue amino-termini to red carboxy-termini. The amino acids missing from VAP-1Δ3 (aa 634-761) are illustrated as gray spheres of different shades. The picture was generated with PyMol <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0054151#pone.0054151-deLano1" target="_blank">[54]</a>.</p
Characteristics of the alternatively spliced transcript of VAP-1.
<p>(<b>A</b>) Schematic presentation of the exon–intron organization of the human VAP-1 gene, <i>AOC3</i>. The boxes with roman numerals (I-IV) represent the exons. The translated regions are shown in <i>color</i> and the 5′- and 3′-untranslated regions in <i>white</i>. Exon III (<i>violet</i>) is spliced out in the shorter splice variant. Sv1: the full-length splice variant; Sv2: the alternatively spliced shorter splice variant. (<b>B</b>) Sequence alignment of the two VAP-1 isoforms. The deduced amino acid sequences of VAP-1 and the shorter isoform VAP-1Δ3. Highlighted are: <i>light yellow,</i> the hydrophobic N-terminal sequence; <i>pink</i>, the conserved signature motif of the active site, in which the first tyrosine is post-translationally modified to topaquinone; <i>lilac</i>, the (putative) catalytic site base; <i>light green</i>, the conserved Cu(II) binding histidine residues; <i>light blue</i>, the conserved cysteine residues involved in dimerization; <i>orange</i> the putative N-linked glycosylation sites, <i>grey</i>, RGD sequence. The amino acids unique to VAP-1Δ3 are in red.</p
VAP-1 cell-surface expression and SSAO activity of transfectants expressing both VAP-1 and VAP-1 Δ3.
<p>HUVECs were first infected with adenoviruses carrying the cDNA for the full-length VAP-1 and then with those carrying the VAP-1Δ3-cDNA. LacZ adenoviruses were used as co-transfection controls. VAP-1 expression was determined by FACS using the antibody JG 2.10. (<b>A</b>) The surface expression of VAP-1 in the transfected cells as mean fluorescence intensities (MFIs) and the averages of MFIs from three experiments. In parentheses, the percentage of VAP-1 surface expression in the co-transfected cells compared to the cells transfected only with VAP-1 ( = 100%). VAP-1Δ3 adenoinfection was performed with two different doses, 400 and 800 pfu (<b>B</b>) A histogram of a representative experiment. The number of cells is shown in the y-axis and the fluorescence in the x-axis. The <i>green</i> histogram shows VAP-1 surface expression in the cells co-infected with the control lacZ adenovirus, the <i>blue</i> histogram shows VAP-1 expression in the cells co-infected with VAP-1Δ3, and the <i>red</i> histogram shows the staining with a negative control antibody. (<b>C</b>) SSAO activity of stably transfected VAP-1-CHO cells co-transfected either with the EGFP-IRES2 empty vector (black) or with the same vector carrying VAP-1Δ3 (white). The enzymatic activity of lysed transfectants was determined in fluorometric assays. The substrates used were <i>BZ</i> benzylamine; <i>MA</i> methylamine (1 mM). Results are shown as nmol of H<sub>2</sub>O<sub>2</sub>/mg/h+SEM. The experiment was repeated four times with MA and five times with BZ.</p
Multivalent Interactions of Human Primary Amine Oxidase with the V and C2<sub>2</sub> Domains of Sialic Acid-Binding Immunoglobulin-Like Lectin-9 Regulate Its Binding and Amine Oxidase Activity
<div><p>Sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9) on leukocyte surface is a counter-receptor for endothelial cell surface adhesin, human primary amine oxidase (hAOC3), a target protein for anti-inflammatory agents. This interaction can be used to detect inflammation and cancer <i>in vivo</i>, since the labeled peptides derived from the second C2 domain (C2<sub>2</sub>) of Siglec-9 specifically bind to the inflammation-inducible hAOC3. As limited knowledge on the interaction between Siglec-9 and hAOC3 has hampered both hAOC3-targeted drug design and <i>in vivo</i> imaging applications, we have now produced and purified the extracellular region of Siglec-9 (Siglec-9-EC) consisting of the V, C2<sub>1</sub> and C2<sub>2</sub> domains, modeled its 3D structure and characterized the hAOC3–Siglec-9 interactions using biophysical methods and activity/inhibition assays. Our results assign individual, previously unknown roles for the V and C2<sub>2</sub> domains. The V domain is responsible for the unusually tight Siglec-9–hAOC3 interactions whereas the intact C2<sub>2</sub> domain of Siglec-9 is required for modulating the enzymatic activity of hAOC3, crucial for the hAOC3-mediated leukocyte trafficking. By characterizing the Siglec-9-EC mutants, we could conclude that R120 in the V domain likely interacts with the terminal sialic acids of hAOC3 attached glycans whereas residues R284 and R290 in C2<sub>2</sub> are involved in the interactions with the active site channel of hAOC3. Furthermore, the C2<sub>2</sub> domain binding enhances the enzymatic activity of hAOC3 although the sialic acid-binding capacity of the V domain of Siglec-9 is abolished by the R120S mutation. To conclude, our results prove that the V and C2<sub>2</sub> domains of Siglec-9-EC interact with hAOC3 in a multifaceted and unique way, forming both glycan-mediated and direct protein-protein interactions, respectively. The reported results on the mechanism of the Siglec-9–hAOC3 interaction are valuable for the development of hAOC3-targeted therapeutics and diagnostic tools.</p></div
The role of sugars, sialic acid binding domain (ΔV) and the mutations R284S, R290S on the binding of Siglec-9-EC to hAOC3.
<p><b>(A)</b> Sialic acid addition decreases the binding of Siglec-9-EC (WT) to hAOC3 by SPR. <b>(B)</b> The effect of the disialyl lactotetraosylceramide (DSLc4) sugar on hAOC3–Siglec-9-EC interaction. Each experiment was performed as duplicate. <b>(C)</b> Relative binding of Siglec-9-EC (WT), -R284S, -R290S, -ΔV, -R120S, R120S/R284 and–R120S/R290S mutants at concentration of 0.5 μM to immobilized hAOC3 (means of two (R120S based mutants)-three experiments are shown ± SEM). *: p<0.05, **:p<0.01 and ***:p<0.001.</p
Purification of Siglec-9-EC from the culture medium.
<p><b>(A)</b> Size exclusion chromatogram of the final purification step for Siglec-9-EC. The fractions from the peak region, marked with double arrow, were collected. The Siglec-9-EC mutants were purified using the same protocol and gave similar curves (data not shown). The calibration curve of the standard proteins, bovine thyroglobulin (670 kDa), bovine Îł-globulin (158 kDa), chicken ovalbumin (44 kDa) and horse myoglobulin (17 kDa), is shown aside the chromatogram. <b>(B)</b> SDS-PAGE analysis of the purified wild-type (WT) sample that was collected from the peak region shown in Fig 2A.</p
Characterization of Siglec-9-EC with the fluorescence-based thermal shift assay.
<p><b>(A)</b> The effect of different buffer pH values on the stability of Siglec-9-EC. The tested buffers were: Citric_pH4 = 100 mM citrate buffer pH 4.0, NaAcetate_pH5 = 100 mM Sodium acetate buffer pH 5.0, MES_pH6 = 100 mM MES buffer pH 6.0, HEPES_pH7 = 100 mM HEPES buffer pH 7.0, Tris-HCl_pH8 = 100 mM Tris-HCl buffer pH 8.0, ImidMaleic_pH 8.5 = 100 mM N-imidazolyl maleamic acid pH 8.5, CHES_pH 9.5 = 100 mM CHES buffer pH 9.5. All of them contained 125 mM NaCl. <b>(B)</b> Thermal shift assay of Siglec-9-EC in 20 mM HEPES buffer, 150mM NaCl, pH 7.4 in the presence of different additives. <b>(C)</b> Thermal shift assay of Siglec-9-EC and the mutant Siglec-9-EC proteins to check the effect of the mutations on the stability of the protein.</p